Effects of GLP-1 receptor agonists on glucose metabolism and its complications in patients with new-onset diabetes after renal transplantation: a prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078600

Enrollment

Unknown

Registered

2023-12-13

Start date

2023-12-15

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

new-onset diabetes after renal transplantation

Interventions

Liraglutide treatment group:Administration of Liraglutide

Metformin treatment group:Administration of Metformin

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Normal and stable graft function after renal transplantation (serum creatinine change < 20% in the last 2 months); (2) estimated glomerular filtration rate =60 ml/min / 1.73 m2 ; (3) in recent 3 months immunosuppression solution stability; (4) according to the WHO confirmed the new hair after renal transplantation diabetes diabetes, diabetes duration less than 12 months, did not use oral glucose-lowering drugs, or into the group stopped oral glucose-lowering drugs before 3 months; ? Age =18 and =75 years old, male or female; ? Body mass index (BMI) =19kg/m2; ? Glycosylated hemoglobin =7% and =10.0%; ? Signed the informed consent and volunteered to participate in this study.

Exclusion criteria

Exclusion criteria: ? Patients with previous or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; ? Patients with previous history of pancreatitis, pancreatitis at the time of screening, serum amylase =3 times the upper limit of normal range, serum triglyceride > 5.6mmol/L, long-term alcohol abuse or gallstones were at high risk of pancreatitis; ? severe gastrointestinal diseases, tumors, severe infections, diabetes ketoacidosis or hypertonic coma; ? pregnant or lactating women or women who plan to become pregnant within 1 year; ? patients with poor ß cell function (C-peptide < 0.3 ng/ml) requiring intensive insulin therapy; ? Mental disorders, cognitive dysfunction and a variety of reasons cause of patients unable to cooperate with the follow-up.

Design outcomes

Primary

Measure	Time frame
Glycosylated hemoglobin;	—

Secondary

Measure	Time frame
Fasting insulin;Bone mineral density;Urinary albumin/creatinine ratio;Blood pressure;	—

Countries

China

Contacts

Public ContactWei Wang

Beijing Chao-yang Hospital, Capital Medical University

weiwang0920@163.com+86 139 1079 0920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026